阿托伐他汀钙治疗急性脑卒中患者的神经功能及胶质纤维酸性蛋白肿瘤坏死因子-α神经元特异性烯醇化酶含量改善分析  

Improvement in neurological function and levels of GFAP, TNF-α and NSE among acute stroke patients treated with atorvastatin calcium

作　　者：金莹 潘敏 陈志阳 包巧惠 洪庆 

机构地区：[1]浙江省温岭市第一人民医院中西医结合科,317500 [2]浙江省温岭市第一人民医院神经内科,317500

出　　处：《中国药物与临床》2018年第2期167-170,共4页Chinese Remedies & Clinics

基　　金：浙江省自然科学基金(LY15H090004)

摘　　要：目的分析阿托伐他汀钙治疗急性脑卒中患者的神经功能及胶质纤维酸性蛋白(GFAP)、肿瘤坏死因子(TNF-α)、神经元特异性烯醇化酶(NSE)含量改善。方法选择2015年1月至2016年10月在我院接受治疗的急性脑卒中患者90例作为研究对象,采用随机数字表法将所有研究对象等分为观察组和对照组,每组45例。对照组采用肠溶阿司匹林等进行常规治疗,观察组患者在此基础上采用阿托伐他汀钙进行治疗。观察2组患者经治疗后的临床疗效、神经功能缺损评分、日常生活能力评分、GFAP、TNF-α、NSE含量以及不良反应情况。结果观察组患者有效率(93%)高于对照组(76%),2组比较差异有统计学意义(P<0.05);2组患者治疗后神经功能缺损评分均有所下降,观察组(7.0±2.0)分低于对照组(8.0±2.4)分,2组比较差异有统计学意义(P<0.05);2组患者治疗后的日常生活能力评分有显著提高,观察组(28±8)分高于对照组(22±7)分,差异有统计学意义(P<0.05);2组患者治疗后GFAP、TNF-α、NSE含量出现显著下降,观察组[(4.3±0.6)μg/L、(7.4±2.2)ng/ml、(8.8±2.3)μg/L]低于对照组[(7.6±1.1)μg/L、(10.4±2.4)ng/ml、(10.3±3.6)μg/L],差异有统计学意义(P<0.05);2组患者在接受治疗期间均未发生严重的不良反应,仅观察患者出现1例恶心症状,自行缓解。结论阿托伐他汀钙对急性脑卒中患者疗效显著,能够有效改善神经功能缺损情况,提高日常生活能力,降低机体GFAP、TNF-α、NSE含量,值得临床推广应用。Objective To evaluate the improvement in neurological function and levels of GFAP, TNF-α and NSE in acute stroke patients treated with atorvastatin calcium. Methods A total of 90 acute stroke patients treated in our hospital between January 2015 and October 2016 were enrolled in this study. The subjects were randomly divided into the study group and control group （n=45 each）. In the control group, enteric-coated aspirin was given as conven- tional treatment, while the patients in the study group were additionally treated with atorvastatin calcium. After treat- ment, the clinical efficacy, neurological deficit score, daily living ability score, levels of GFAP, TNF-α and NSE, and adverse reactions were compared between the two groups. Results The effective rate was 93% in the study group, which was significantly higher than that （76%） in the control group （P〈0.05）. While the neurological deficit score de- creased after treatment in both groups, the score in the study group （7.0±2.0） was significantly lower than that （8.0＋ 2.4） in the control group （P〈0.05）. While the daily living ability score was significantly increased in both groups after treatment, the score in the study group （28_＋8） was significantly higher than that （22±7） in the control group （P〈0.05）. While the levels of GFAP, TNF-α and NSE in the two groups were significantly decreased after treatment, the levels in the study group [（4.3±0.6） μg/L, （7.4±2.2） ng/ml, （8.8±2.3） μg/L] were significantly lower than those [（7.6±1.1） μg/L, （10.4±2.4） ng/ml, （10.3±3.6） μg/L] in the control group （P〈0.05）. No severe adverse reactions occurred in both groups during the course of treatment. Only one patient in the study group showed nausea and relieved spontaneously. Conclusion Atorvastatin calcium offers significant therapeutic efficaey in patients with acute stroke in improving neurological deficits, daily living ability and GFAP, TNF-α and NSE levels, and is therefore wort

关 键 词：阿托伐他汀钙 脑血管意外 神经功能 胶质纤维酸陛蛋白 肿瘤坏死因子α 

分 类 号：R743.3[医药卫生—神经病学与精神病学]